Citations

Clear

99 citation(s) found for "Romano, D".

Prediction of Right Ventricular Failure After Ventricular Assist Device Implant: Systematic Review and Meta-Analysis of Observational Studies
Bellavia, Diego , Scardulla, Cesare, Moja, Lorenzo , Pilato, Michele , Kushwaha, Sudhir S. , Senni, Michele , Clemenza, Francesco , Agnese, Valentina , Falletta, Calogero , Romano, Giuseppe , Maalouf, Joseph F., Dandel, Michael , Iacovoni, Attilio , Senni, Michele

Mayo Clinic

European Journal of Heart Failure | March 31, 2017 | Volume: 19 | Issue: 7 | Pages: 926-946

10.1002/ejhf.733 | PMID 28371221 Get It

Abstract Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is associated with increased morbidity and mortality, but the identification of LVAD candidates at risk for RVF remains challenging. We undertook a systematic review and meta-analysis of observational studies of risk factors associated with RVF after LVAD implant. Thirty-six studies published between 1 January 1995 and 30 April 2015, comprising 995 RVF patients out of a pooled final population of 4428 patients, were identified. Meta-analysed prevalence of post-LVAD RVF was 35%. A need for mechanical ventilation [odds ratio (OR) 2.99], or continuous renal replacement therapy (CRRT; OR 4.61, area under the curve 0.78, specificity 0.91) were the clinical variables with the highest effect size (ES) in predicting RVF. International normalized ratio [INR; standardized mean difference (SMD) 0.49] and N-terminal pro-brain natriuretic peptide (NT-proBNP) (SMD 0.52) were the biochemical markers that best discriminated between RVF and No-RVF populations, though NT-proBNP was highly heterogeneous. Right ventricular stroke work index (RVSWI) and central venous pressure (CVP) (SMD −0.58 and 0.47, respectively) were the haemodynamic measures with the highest ES in identifying patients at risk of post-LVAD RVF; CVP was particularly useful in risk stratifying patients undergoing continuous-flow LVAD implant (SMD 0.59, P < 0.001, I2 = 20.9%). Finally, pre-implant moderate to severe right ventricular (RV) dysfunction, as assessed qualitatively (OR 2.82), or a greater RV/LV diameter ratio (SMD 0.51) were the standard echocardiographic measurements with the highest ES in comparing RVF with No-RVF patients. Longitudinal systolic strain of the RV free wall had the highest ES (SMD 0.73) but also the greatest heterogeneity (I2 = 74%) and was thus only marginally significant (P = 0.05). Patients on ventilatory support or CRRT are at high risk for post-LVAD RVF, similarly to patients with slightly increased INR, high NT-proBNP or leukocytosis. High CVP, low RVSWI, an enlarged right ventricle with concomitant low RV strain also identify patients at higher risk.
A phase I safety and pharmacokinetic (PK) study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients (pts) with advanced pancreatic cancer (APC) who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction.
Riess, Hanno, Kunzmann, Volker , Philip, Philip Agop, Seufferlein, Thomas , McGovern, D., Chen, Peng , Romano, Alfredo, Ramanathan, Ramesh K.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 4_suppl | Pages: TPS474-TPS474

10.1200/jco.2016.34.4_suppl.tps474 Get It

TPS474 Background: In pts with APC, the distal common bile duct is frequently obstructed, which can lead to elevated bilirubin levels. Normalization of bilirubin by stenting can take weeks, so treatment options that could be initiated in pts with elevated bilirubin are desirable. In a phase III trial of pts with metastatic PC, nab-P + Gem demonstrated superior efficacy vs Gem alone for all endpoints, including overall survival (OS; median, 8.7 vs 6.6 months; hazard ratio, 0.72; P < 0.001). This study will be the first to analyze safety and PK profiles of nab-P + Gem in pts with APC and CH secondary to bile duct obstruction. Methods: Treatment-naive pts (≈ 12 to 40) with APC, Karnofsky performance status ≥ 70, and CH due to bile duct obstruction are eligible. Pts with a biliary stent must have 2 stable (within 20% of each other) bilirubin readings within 48 to 72 hours of each other taken between 5 and 21 days after stenting. Exclusion criteria consist of brain metastases, any other active malignancy, infection requiring systemic therapy, a history of myocardial infarction, or current use of medications known to be strong inducers of CYP3A4 and CYP2C8. Pts will enter 1 of 2 cohorts based on bilirubin level: cohort 1, > 1.5 to 3 × upper limit of normal (ULN), or cohort 2, > 3 to 5 × ULN. Cohort 2 will proceed only after review of safety and PK data from cohort 1 by a safety monitoring committee (SMC) and a decision has been made to proceed. The starting doses are nab-P 100 mg/m2 and Gem 800 mg/m2 for cohort 1 and nab-P 75 mg/m2 and Gem 600 mg/m2 for cohort 2. Treatment will be administered on days 1, 8, and 15 of each 28-day cycle. Doses in each cohort will be modified according to tolerability as determined by the SMC. The primary endpoints are determination of maximum tolerated dose for each cohort and PK profile. Secondary endpoints include investigator-assessed objective response rate, progression-free survival, OS, PK profile of Gem, and safety. The exploratory endpoint is change in serum CA19-9 level from baseline. Enrollment is ongoing. ClinicalTrials.gov: NCT02267707. Clinical trial information: NCT02267707.
Slip interface imaging based on MR‐elastography preoperatively predicts meningioma–brain adhesion
Yin, Ziying , Hughes, Joshua , Glaser, Kevin J. , Link, Michael J. , Romano, Anthony J., Hughes, Joshua D, Trzasko, Joshua D. , Van Gompel, Jamie, Manduca, Armando , Gompel, Jamie J. Van , Ehman, Richard L. , Huston, John , Yin, Ziying

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 14, 2017 | Volume: 46 | Issue: 4 | Pages: 1007-1016

10.1002/jmri.25623 | PMID 28194925 Get It

PurposeTo investigate the ability of slip interface imaging (SII), a recently developed magnetic resonance elastography (MRE)‐based technique, to predict the degree of meningioma–brain adhesion, using findings at surgery as the reference standard.Materials and MethodsWith Institutional Review Board approval and written informed consent, 25 patients with meningiomas >2.5 cm in maximal diameter underwent preoperative SII assessment. Intracranial shear motions were introduced using a soft, pillow‐like head driver and the resulting displacement field was acquired with an MRE pulse sequence on 3T MR scanners. The displacement data were analyzed to determine tumor–brain adhesion by assessing intensities on shear line images and raw as well as normalized octahedral shear strain (OSS) values along the interface. The SII findings of shear line images, OSS, and normalized OSS were independently and blindly correlated with surgical findings of tumor adhesion by using the Cohen's κ coefficient and chi‐squared test.ResultsNeurosurgeons categorized the surgical plane as extrapial (no adhesion) in 15 patients, mixed in four, and subpial (adhesion) in six. Both shear line images and OSS agreed with the surgical findings in 18 (72%) cases (fair agreement, κ = 0.37, 95% confidence interval [CI]: 0.05–0.69), while normalized OSS was concordant with the surgical findings in 23 (92%) cases (good agreement, κ = 0.86, 95% CI: 0.67–1). The correlation between SII predictions (shear line images, OSS, and normalized OSS) and the surgical findings were statistically significant (chi‐squared test, P = 0.02, P = 0.02, and P < 0.0001, respectively).ConclusionSII preoperatively evaluates the degree of meningioma–brain adhesion noninvasively, allowing for improved prediction of surgical risk and tumor resectability.Level of Evidence: 1Technical Efficacy: Stage 1J. Magn. Reson. Imaging 2017;46:1007–1016.
Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes
Russo, Arianna, Scardigli, Raffaella , Regina, Federico La, Murray, Melissa E. , Ceci, Marcello , Romano, Nicla , Dickson, Dennis W. , Wolozin, Benjamin , Cattaneo, Antonino , Murray, Melissa E

Mayo Clinic

Human Molecular Genetics | February 3, 2017 | Volume: 26 | Issue: 8 | Pages: 1407-1418

10.1093/hmg/ddx035 | PMID 28158562 Get It

High Relative Expression of Pannexin 3 (PANX3) in an Axillary Sweat Gland Carcinoma With Osteosarcomatous Transformation
Romano, Ryan C., Ram, Roopa , Govindarajan, Rang, Montgomery, Corey , Gilley, Jasen, Nicholas, Richard W. , Gardner, Jerad M , Shalin, Sara C.

Mayo Clinic

The American Journal of Dermatopathology | July 8, 2016 | Volume: 38 | Issue: 11 | Pages: 846-851

10.1097/dad.0000000000000583 | PMID 27391460 Get It

Abstract: Primary cutaneous sweat gland carcinomas (SGCs) are rare tumors that commonly involve axillae, have a high local recurrence rate, and rarely show sarcomatoid transformation. A 68-year-old man presented with rapid enlargement of a previously stable, asymptomatic pea-sized nodule in the left axilla. Initial excision (with positive surgical margins) at another institution showed characteristic histologic features of a high-grade osteosarcoma and molecular analysis using a 92-gene real-time quantitative reverse transcription–polymerase chain reaction assay confirmed a diagnosis of osteosarcoma with 96% certainty. Notably, the molecular assay demonstrated consistently high relative expression of pannexin 3 (PANX3), a gene involved in normal osteoblast differentiation which, when highly expressed, strongly predicts osteosarcoma per the assay's algorithm. However, on further histologic review, the tumor also contained focal cystic areas, nests, and ducts composed of malignant epithelial cells reminiscent of SGC; these areas directly transitioned into the osteosarcomatous component and were strongly positive for pancytokeratin, CK7, and p63. Within 2 weeks, the lesion recurred and grew rapidly, prompting complete resection, histologic sections of which showed high-grade osteosarcoma without residual epithelial elements. This is the fifth report, to our knowledge, of osteosarcomatous transformation in a SGC, and the only report to date including molecular data. This case demonstrates that osteosarcoma arising from a SGC has a similar molecular profile to de novo primary osteosarcoma of bone. It also emphasizes the importance of histopathologic findings as the established diagnostic gold standard and the need to interpret molecular results within the clinical context.
Malignant Melanoma of the Nail Apparatus
Romano, Ryan C., Shon, Wonwoo , Sukov, William R.

Mayo Clinic

International Journal of Surgical Pathology | May 16, 2016 | Volume: 24 | Issue: 6 | Pages: 512-518

10.1177/1066896916648379 | PMID 27185405 Get It

Background. Malignant melanoma of the nail apparatus is exceedingly rare. Increasingly, genetic studies have been employed to aid in distinguishing between malignant melanoma and benign melanocytic nevi. Methods. Archived nail apparatus melanomas were analyzed by fluorescence in situ hybridization (FISH) using probes targeting the genes at 6p25 (RREB1), 11q13 (CCND1), 8q24.1 (MYC), 6q23 (MYB), 9p21 (CDKN2A) and the centromeres of chromosomes 8 (D8Z2) and 6 (D6Z1). The results were correlated with clinical and demographic information. Results. Mean patient age was 57.8 years (range 23-92 years). In all, 5 of 7 (71%) cases involved the upper extremity digits. RREB1 gain was seen in all cases. CCND1 gain was seen in 6 of 7 (86%) cases, 3 of which were amplified. MYB loss and MYC gain were both seen in 5 of 7 (71%) cases. Homozygous loss of CDKN2A was not observed in any case. Two of 7 (28.6%) patients had lymph node metastasis and died of widely metastatic disease. These 2 patients harbored the most genetic aberrations: gains of RREB1, CCND1, and MYC, and MYB loss. Both benign melanocytic nevi controls showed normal FISH results. Conclusions. RREB1 and CCND1 gains are common in nail apparatus melanoma as in most melanomas, and an increased number of genetic aberrations may be associated with a poorer prognosis, though the limited number of cases precludes definitive correlation. FISH appears to be a useful adjunct in the diagnosis of nail apparatus melanomas and improves diagnostic confidence even in the setting of unambiguous histomorphology.
Recurrent duplications of 17q12 associated with variable phenotypes
Mitchell, Elyse, Douglas, Andrew G. L. , Kjaegaard, Susanne, Callewaert, Bert , Janssens, Sandra , Yuen, Amy Lawson, Skinner, Cindy , Failla, Pinella , Alberti, A , Avola, Emanuela , Fichera, Marco , Kibæk, Maria, Digilio, M. Cristina , Hannibal, Mark , Hollander, Nicolette S. den , Bizzarri, Veronica, Renieri, Alessandra , Mencarelli, Maria Antonietta , Fitzgerald, Tomas , Piazzolla, Serena, Oudenhove, Elke Van , Romano, Corrado , Schwartz, Charles E. , Rajan, Diana, Crolla, John A., Carter, Nigel, Hodge, Jennelle C. , Vanlander, Arnaud Vincent , Eichler, Evan E , Slavotinek, Anne , Escobar, Luis Fernando , Mefford, Heather C. , Callewaert, Bert , Renieri, Alessandra

Mayo Clinic

American Journal of Medical Genetics Part A | September 30, 2015 | Volume: 167 | Issue: 12 | Pages: 3038-3045

10.1002/ajmg.a.37351 | PMID 26420380 Get It

The ability to identify the clinical nature of the recurrent duplication of chromosome 17q12 has been limited by its rarity and the diverse range of phenotypes associated with this genomic change. In order to further define the clinical features of affected patients, detailed clinical information was collected in the largest series to date (30 patients and 2 of their siblings) through a multi‐institutional collaborative effort. The majority of patients presented with developmental delays varying from mild to severe. Though dysmorphic features were commonly reported, patients do not have consistent and recognizable features. Cardiac, ophthalmologic, growth, behavioral, and other abnormalities were each present in a subset of patients. The newly associated features potentially resulting from 17q12 duplication include height and weight above the 95th percentile, cataracts, microphthalmia, coloboma, astigmatism, tracheomalacia, cutaneous mosaicism, pectus excavatum, scoliosis, hypermobility, hypospadias, diverticulum of Kommerell, pyloric stenosis, and pseudohypoparathryoidism. The majority of duplications were inherited with some carrier parents reporting learning disabilities or microcephaly. We identified additional, potentially contributory copy number changes in a subset of patients, including one patient each with 16p11.2 deletion and 15q13.3 deletion. Our data further define and expand the clinical spectrum associated with duplications of 17q12 and provide support for the role of genomic modifiers contributing to phenotypic variability. © 2015 Wiley Periodicals, Inc.
The Essential Role of Pathologists in Health Care and Health Policy
Romano, Ryan C., Allen, Timothy Craig, Blessing, Melissa M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 31, 2015 | Volume: 139 | Issue: 4 | Pages: 441-444

10.5858/arpa.2014-0335-ed | PMID 25822761 Get It

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
Tabernero, Josep , Chiorean, E. Gabriela , Infante, Jeffrey R., Hingorani, Sunil R. , Ganju, Vinod , Weekes, Colin D. , Scheithauer, Werner, Ramanathan, Ramesh K., Goldstein, David , Penenberg, Darryl, Romano, Alfredo, Ferrara, Stefano, Hoff, Daniel D. Von , Infante, Jon , Weekes, Colin, Penenberg, Darryl N, Von Hoff, Daniel D, Tabernero, Josep , Infante, Jon

Mayo Clinic

The Oncologist | January 13, 2015 | Volume: 20 | Issue: 2 | Pages: 143-150

10.1634/theoncologist.2014-0394 | PMID 25582141 Get It

Abstract Background. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presence of liver metastases were shown to be predictive of survival with nab-paclitaxel plus gemcitabine treatment. This analysis sought to further explore the relationship between clinical characteristics and survival in the MPACT trial and to identify potential predictors of overall survival and progression-free survival in patients with MPC. Materials and Methods. Cox regression models adjusted for stratification factors and a stepwise multivariate analysis of prespecified baseline prognostic factors were performed. Results. Treatment effect was significantly associated with survival, with a similar magnitude of reduction in risk of death compared with the previously reported primary analysis. Treatment effect consistently favored nab-paclitaxel plus gemcitabine across the majority of the prespecified factors. In addition to KPS score and presence of liver metastases, age and number of metastatic sites were independent prognostic factors of overall and progression-free survival. Baseline carbohydrate antigen 19-9 was not found to be an independent prognostic factor of survival in this analysis. Conclusion. The results of this analysis confirm broad utility of nab-paclitaxel plus gemcitabine for the treatment of MPC. In addition, these findings suggest that KPS score, presence of liver metastases, age, and number of metastatic sites are important predictors of survival that may be useful when making treatment decisions and designing future clinical trials.
Phakomatous Choristoma in a 10‐Week‐Old Boy: A Case Report and Review of the Literature
Romano, Ryan C., McDonough, Patrick M., Salomão, Diva R. , Fritchie, Karen , Fritchie, Karen J.

Mayo Clinic

Pediatric Dermatology | December 30, 2014 | Volume: 32 | Issue: 3 | Pages: 405-409

10.1111/pde.12493 | PMID 25557852 Get It

AbstractPhakomatous choristoma (PC) is a rare benign congenital lesion of lenticular anlage. It presents in young patients as a firm subcutaneous mass in the medial eyelid or orbit and may raise clinical concern for neoplasms such as rhabdomyosarcoma, but its histopathology is distinct, consisting of dense collagenous stroma and eosinophilic cuboidal epithelial cells forming nests, tubules, cords, or pseudoglands. We present a case of PC in a 10‐week‐old boy to illustrate the unique clinical, histopathologic, and immunophenotypic features of this condition and to reaffirm that familiarity with this rare entity aids accurate diagnosis.